Rosenthal and collaborators (2015) described the results of the first-in-human clinical trial using cetuximab conjugated to IRDye® 800CW to guide the surgery of head and neck squamous cell carcinoma and the fluorescence was correlated to EGFR expression of the tumor. This evidence concerns the gene EGFR and neoplasm.